Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma

Cuproptosis-related lncRNA signatures predict prognosis and immune relevance of kidney renal papillary cell carcinoma

Kidney renal papillary cell carcinoma (KIRP) has a high mortality rate and a poor prognosis. Cu concentrations differed significantly between renal cancer tissues and adjacent normal tissues. Cuproptosis is a newly identified cell death. Long non-coding RNAs (lncRNAs) play a crucial role in the prog...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Tongjin Xie, Bin Liu, Dongbo Liu, Yusong Zhou, Qingping Yang, Dai Wang, Mengjie Tang, Wei Liu
Format:	Artikel
Sprache:	English
Veröffentlicht:	Frontiers Media S.A. 2022-12-01
Schriftenreihe:	Frontiers in Pharmacology
Schlagworte:	lncRNA cuproptosis KIRP prognosis immune relevance
Online Zugang:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1103986/full

Ähnliche Einträge

A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer
von: Yuchen Bai, et al.
Veröffentlicht: (2022-11-01)

A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA
von: Mingyi Yang, et al.
Veröffentlicht: (2022-07-01)

Ferroptosis-Related lncRNA to Predict the Clinical Outcomes and Molecular Characteristics of Kidney Renal Papillary Cell Carcinoma
von: Yubo Gong, et al.
Veröffentlicht: (2024-02-01)

Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma
von: Binfeng Liu, et al.
Veröffentlicht: (2022-10-01)

A cuproptosis-related lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma
von: Jingyi Wu, et al.
Veröffentlicht: (2023-09-01)

Cuproptosis related lncRNA signature as a prognostic and therapeutic biomarker in osteosarcoma immunity
von: Ziwei Gao, et al.
Veröffentlicht: (2025-01-01)

Cuproptosis-related lncRNA signatures: Predicting prognosis and evaluating the tumor immune microenvironment in lung adenocarcinoma
von: Pengpeng Zhang, et al.
Veröffentlicht: (2023-01-01)

Prognosis and immune response of a cuproptosis-related lncRNA signature in low grade glioma
von: Yifan Xu, et al.
Veröffentlicht: (2022-10-01)

Cuproptosis-related lncRNA: Prediction of prognosis and subtype determination in clear cell renal cell carcinoma
von: Youlong Huili, et al.
Veröffentlicht: (2022-08-01)

Construction of five cuproptosis-related lncRNA signature for predicting prognosis and immune activity in skin cutaneous melanoma
von: Xiaojing Yang, et al.
Veröffentlicht: (2022-09-01)

Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer
von: Jia Chen, et al.
Veröffentlicht: (2022-12-01)

Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning
von: Zhixun Bai, et al.
Veröffentlicht: (2022-12-01)

Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients
von: Zi-Rong Jiang, et al.
Veröffentlicht: (2022-09-01)

Identification of a novel prognostic cuproptosis-associated LncRNA signature for predicting prognosis and immunotherapy response in patients with esophageal cancer
von: Xinhai Sun, et al.
Veröffentlicht: (2024-05-01)

Prognostic Significance and Immune Landscape of a Cuproptosis-Related LncRNA Signature in Ovarian Cancer
von: Min Zhou, et al.
Veröffentlicht: (2024-11-01)

A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma
von: Zheng Zhou, et al.
Veröffentlicht: (2023-03-01)

In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma
von: Yue Wang, et al.
Veröffentlicht: (2022-09-01)

Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma
von: Shusheng Zhu, et al.
Veröffentlicht: (2023-07-01)

Comprehensive analysis of a novel cuproptosis-related lncRNA signature associated with prognosis and tumor matrix features to predict immunotherapy in soft tissue carcinoma
von: Binfeng Liu, et al.
Veröffentlicht: (2022-12-01)

Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer
von: Chun Li, et al.
Veröffentlicht: (2023-07-01)

Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia
von: Yidong Zhu, et al.
Veröffentlicht: (2023-02-01)

Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma
von: Xiaoping Wang, et al.
Veröffentlicht: (2023-02-01)

A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma
von: Jun Wen, et al.
Veröffentlicht: (2023-01-01)

Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma
von: Xiaoran Bai, et al.
Veröffentlicht: (2024-06-01)

Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma
von: Miaorong Xu, et al.
Veröffentlicht: (2022-07-01)

Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer
von: Xinyu Liu, et al.
Veröffentlicht: (2022-09-01)

Cuproptosis-related LncRNAs signature as biomarker of prognosis and immune infiltration in pancreatic cancer
von: Hui Chen, et al.
Veröffentlicht: (2023-01-01)

Identification and validation of cuproptosis-related LncRNA signatures as a novel prognostic model for head and neck squamous cell cancer
von: Xiajing Liu, et al.
Veröffentlicht: (2022-11-01)

Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs
von: Mingwei Wei, et al.
Veröffentlicht: (2024-04-01)

Construction and comprehensive analysis of a curoptosis-related lncRNA signature for predicting prognosis and immune response in cervical cancer
von: Li Liu, et al.
Veröffentlicht: (2023-01-01)

Prognosis and personalized treatment prediction in lung adenocarcinoma: An in silico and in vitro strategy adopting cuproptosis related lncRNA towards precision oncology
von: Chao Ma, et al.
Veröffentlicht: (2023-02-01)

Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma
von: Shengxian Xu, et al.
Veröffentlicht: (2022-07-01)

Based on cuproptosis-related lncRNAs, a novel prognostic signature for colon adenocarcinoma prognosis, immunotherapy, and chemotherapy response
von: Chong Li, et al.
Veröffentlicht: (2023-06-01)

Prediction of immune infiltration and prognosis for patients with cholangiocarcinoma based on a cuproptosis-related lncRNA signature
von: Hong-Fei Yao, et al.
Veröffentlicht: (2024-01-01)

Construction of a cuproptosis-associated lncRNA prognostic signature for bladder cancer and experimental validation of cuproptosis-related lncRNA UBE2Q1-AS1
von: Junlin Shen, et al.
Veröffentlicht: (2023-08-01)

Identification of a novel cuproptosis-associated lncRNA model that can improve prognosis prediction in uterine corpus endometrial carcinoma
von: Bohan Li, et al.
Veröffentlicht: (2023-12-01)

Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer
von: Lin Pang, et al.
Veröffentlicht: (2023-03-01)

Cuproptosis-associated lncRNAs discern prognosis and immune microenvironment in sarcoma victims
von: Binxiang Chu, et al.
Veröffentlicht: (2022-12-01)

A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer
von: Lei Ren, et al.
Veröffentlicht: (2023-02-01)

A cuproptosis-related lncRNA signature-based prognostic model featuring on metastasis and drug selection strategy for patients with lung adenocarcinoma
von: Mengzhe Zhang, et al.
Veröffentlicht: (2023-09-01)